Gilead Sciences
The Domain Architect role at Gilead supports the evolution of Commercial technology capabilities by partnering with stakeholders to design scalable, compliant, and business-aligned solutions. This position serves as a bridge between business strategy, domain architecture, and solution delivery, ensuring technology investments align with enterprise standards and target-state architecture. The role contributes to architecture governance, technology planning, and modernization initiatives across Commercial IT, Data & Analytics, and AI-enabled platforms.
Headquarters
Foster City, California, United States
Company Size
10001+ employees
Founded
1987
Gilead Sciences is a biopharmaceutical company dedicated to transforming patient care by advancing therapeutics in areas like HIV, liver disease, cancer, and inflammation. With a strong commitment to innovation, Gilead leads in the research and development of new medicines, aiming to make the world a healthier place. Their portfolio includes breakthrough therapies and ongoing advancements across multiple therapeutic areas, supported by a robust pipeline of clinical trials. Gilead is recognized for its contributions to public health and its efforts to improve access to vital medications.
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD
4 hours ago
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals
1 hour ago
Jefferies initiates Gilead Sciences stock with buy rating
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Gilead Sciences.
Gilead Sciences didn’t post a salary, so this is our estimate from similar listings.
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
2 days ago